MedTrace Logo

Immune Monitoring of Hepatitis C Under DAA Therapy

NCT02904603 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-09-21

No results posted yet for this study

Summary

Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.

Conditions

  • Hepatitis C

Sponsors & Collaborators

  • University of Regensburg

    lead OTHER

Principal Investigators

  • Kilian Weigand · Uiversity of Regensburg

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-11-30
Completion
2017-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02904603 on ClinicalTrials.gov